Challenges and perspective of drug repurposing strategies in early phase clinical trials
Authors:
Open Access
- 30 June 2015
- journal article
- Published by Impact Journals, LLC in Oncoscience
- Vol. 2 (6) , 576-580
Abstract
Despite significant investments in the development of new agents only 5% of cancer drugs entering Phase I clinical trials are ultimately approved for routine clinical cancer care. Drug repurposing strategies using novel combinations of previously tested anticancer agents could reduce the cost and improve treatment outcomes. At MD Anderson Cancer Center, early phase clinical trials with drug repurposing strategies demonstrated promising outcomes in patients with both rare and common treatment refractory advanced cancers. Despite clinical efficacy advancing drug repurposing strategies in the clinical trial trajectory beyond early phase studies has been challenging mainly due to lack of funding and interest from the pharmaceutical industry. In this review, we delineate our experience and challenges with drug repurposing strategies.Keywords
This publication has 27 references indexed in Scilit:
- Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancerAnnals of Oncology, 2013
- Cancer drug discovery by repurposing: teaching new tricks to old dogsTrends in Pharmacological Sciences, 2013
- Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancerOncotarget, 2013
- Phase I Study of the Antiangiogenic Antibody Bevacizumab and the mTOR/Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin: Tolerance and Biological ActivityClinical Cancer Research, 2012
- CrizotinibNature Reviews Drug Discovery, 2011
- A Phase I Trial of Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Patients with Advanced Gynecologic and Breast MalignanciesClinical Cancer Research, 2011
- A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517Leukemia & Lymphoma, 2011
- Responses to Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Metaplastic Carcinoma of the Breast: Biologic Rationale and Implications for Stem-Cell Research in Breast CancerJournal of Clinical Oncology, 2011
- Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway.2003
- Metaplastic breast cancer: Prognosis and response to systemic therapyAnnals of Oncology, 1999